+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B



Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B



Scandinavian Journal of Gastroenterology 44(8): 1021-1022




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056572889

Download citation: RISBibTeXText

PMID: 19424932

DOI: 10.1080/00365520902937370


Related references

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology and Hepatology 22(10): 1582-1588, 2007

Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrobial Agents and ChemoTherapy 51(8): 3020-3022, 2007

A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. Hepatology 42(1): 77-85, 2005

Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Medical Science Monitor 15(2): Cr56-Cr61, 2009

Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B. Journal of Hepatology 38(Suppl. 2): 169, 2003

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454): 123-129, 2005

Pegylated Interferon Alfa-2b Alone or in Combination With Lamivudine for HBeAg-Positive Chronic Hepatitis B: A Randomised Trial. Yearbook of Gastroenterology 2006: 273-274, 2006

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastro-Enterologica Belgica 70(1): 20-24, 2007

A randomized trial of peginteferon alfa-2b and lamivudine combination treatment versus lamivudine monotherapy in Chinese patients with HBeAg-positive chronic hepatitis B. Journal of Hepatology 40(Suppl 1): 125-126, 2004

HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype. Le Infezioni in Medicina 24(2): 144-146, 2017

Comparison of efficacy of pegylated interferon alfa-2a or interferon alfa-2b combination therapy with nucleus(t)ide analogues in HBeAg positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 19(10): 785-786, 2012

Comparison of lamivudine monotherapy with lamivudine plus interferon alpha combination in patients with HBeAg positive chronic hepatitis B. Journal of Hepatology 34(Suppl. 1): 177-178, 2001

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. American Journal of Gastroenterology 100(11): 2463-2471, 2005

HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?. Liver International 34(Suppl. 1): 127-132, 2014